The Biosafety Level-3 (BL-3) Core Facility is designed to provide an efficient, cost-effective, and safe environment for CFAR and other investigators involved in AIDS and AIDS-related research such that both ongoing projects will benefit and new collaborations will be fostered. Since culture of biohazardous pathogens including HIV, SIV, HTLV-I and virulent M. tuberculosis is an absolute requirement for many CFAR investigators, this facility is essential. The new BL-3 Facility (1127 sq ft) is scheduled for completion in October 1993, and is located on the 10th floor of the Biomedical Research Building, in the Division of Infectious Disease. The Facility has recently been equipped to the greater extent by the CWRU School of Medicine. Equipment includes 5 laminar flow hoods, centrifuges, incubators, -70C freezers, microscopes, thermal cycler and ELISA reader. The Facility is comprised of 6 rooms, the 3 largest for biohazardous activities. One room will be devoted to research involving virulent M. tuberculosis and another to HIV, SIV, and HTLV-I. Other rooms house common equipment. The BL-3 Core Facility will be administered by a BL-3 Advisory Group comprised of members of the CFAR; Dr. Rich (Director of the BL-3 Core Facility), Dr. LeGrice, and De. Lederman. Dr. Rich's laboratory is adjacent to the BL-3 Facility. Projects performed in the BL-3 Facility will be established beginning in funding year 02 to cover costs of the Facility such that by year 05, 70% of these will be generated by such fees. Multidisciplinary collaboration will be fostered by the BL-3 Core Facility by three main mechanisms: 1) Through interactions among users of the facility; 2) Through services rendered by a full-time research assistant in the facility including viral stock preparation, HIV infections of cells, p24 ELISAs, and teaching of these techniques to new investigators. 3) Quarterly meetings by all users and interested faculty discussing results obtained from experiments performed in the facility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-03
Application #
5205753
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications